Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

Journal of Hepatology

Volumn 60, Issue 3, 2014, Pages 530-537

  Younossi, Zobair M ^a   Singer, Mendel E ^b   Mir, Heshaam M ^a,c   Henry, Linda ^c   Hunt, Sharon ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Cost effectiveness analysis; DAA; HCV; Interferon free oral treatment; Markov model

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

CLASSIFICATION; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; GENOTYPE; HEALTH CARE COST; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; VIROLOGY;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84894068078     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.11.009     Document Type: Article

References (50)

1. L. Gravitz Introduction: a smouldering public-health crisis Nature 474 2011 S2 S4
2. E. Chak, A.H. Tala, and K.E. Sherman et al. Hepatitis C virus infection in the USA: an estimate of true prevalence Liver Int 31 2011 1090 1101
3. K.N. Ly, J. Xing, R.M. Klevens, R.B. Jiles, J.W. Ward, and S.D. Holmberg The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 Ann Intern Med 156 2012 271 278
4. Institute of Medicine Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C 2010 The National Academies Press Washington, DC
5. J. Moon, J. Kallman, P. Winter, M. Srishord, Y. Fang, and L. Gerber et al. Disparities in activity level and nutrition between patients with chronic hepatitis C and blood donors PMR 4 2012 436 441 10.1016/j.pmrj.2012.02.020 [Epub 2012 Apr 28]
6. G.R. Foster, S. Zeuzem, P. Andreone, S. Pol, E.J. Lawitz, and M. Diago et al. Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure J Hepatol 58 2013 488 494 10.1016/j.jhep.2012.11.013 [Epub 2012 Nov 23]
7. Pyenson B, Fitch K, Iwasaki K. Consequences of Hepatitis C Virus (HCV): Costs of a baby boomer epidemic of liver disease. New York, NY: Milliman, Inc; May 18, 2009. [Internet, cited 2013 Mar 12]. Available from: < http://publications.milliman.com/research/health-rr/pdfs/consequences-hepatitis- c-virus-RR05-18-09.pdf >.
8. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
9. D.B. Rein, B.D. Smith, J.S. Wittenborn, S.B. Lesesne, L.D. Wagner, and D.W. Roblin et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings Ann Intern Med 156 2012 263 270
10. J.B. Wong, G.M. McQuillan, J.G. McHutchison, and T. Poynard Estimating future hepatitis C morbidity, mortality, and costs in the United States Am J Public Health 90 2000 1562 1569
11. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516 e1
12. R.L. Morgan, B. Baack, B.D. Smith, A. Yartel, M. Pitasi, and Y. Falck-Ytter Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies Ann Intern Med 158 2013 329 337
13. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, and F. Lammert et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
14. FDA NEWS RELEASE: FDA approves Incivek for hepatitis C; May 23, 2011. [Internet, cited 2013 April 02]. Available from: < http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm >.
15. FDA Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV) May 13, 2011. [Internet, cited 2013 April 02]. Available from: < http://www.fda.gov/ForConsumers/ByAudience/ ForPatientAdvocates/ucm255413.htm >.
16. C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441 10.1016/j.jhep.2013.04.035 [Epub 2013 May 10]
17. Everson GT, Sims KD, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naïve patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. Program and abstracts of the 63rd annual meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, Massachusetts. Abstract LB-3.
18. Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. Program and abstracts of the 63rd annual meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, Massachusetts. Abstract 229.
19. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. Program and abstracts of the 63rd annual meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, Massachusetts. Abstract LB-1.
20. Osinusi A, Heytens L, Lee Y, et al. High efficacy of GS-7977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients: interim analysis from the SPARE trial. Program and abstracts of the 63rd annual meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, Massachusetts. Abstract LB-4.
21. M.S. Sulkowski, F. Poordad, M.P. Manns, J.-P. Bronowicki, K. Rajender Reddy, and S.A. Harrison et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial Hepatology 57 2013 974 984
22. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
23. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
24. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
25. P. Pradat, N. Voirin, H.L. Tillmann, M. Chevallier, and C. Trépo Progression to cirrhosis in hepatitis C patients: an age-dependent process Liver Int 27 2007 335 339
26. S. Bruno, M. Zuin, A. Crosignani, S. Rossi, F. Zadra, and L. Roffi et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study Am J Gastroenterology 104 2009 1147 1158
27. J.A. Salomon, M.C. Weinstein, J.K. Hammitt, and S.J. Goldie Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population JAMA 290 2003 228 237
28. R. Planas, B. Ballesté, M.A. Alvarez, M. Rivera, S. Montoliu, and J.A. Galeras et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients J Hepatol 40 2004 823 830
29. L.J. McGarry, V.S. Pawar, H.R. Panchmatia, J.L. Rubin, G.L. Davis, and Z.M. Younossi et al. Economic model of a birth cohort screening program for hepatitis C virus Hepatology 55 2012 1344 1355
30. M.E. Singer, and Z.M. Younossi Cost-effectiveness of screening for hepatitis C virus in asymptomatic, average risk adults: has the time come? Am J Med 111 2001 614 621
31. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, and P. Almasio et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
32. M.K. Miriti, K. Billah, C. Weinbaum, J. Subiadur, R. Zimmerman, and P. Murray et al. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S Public Health Rep 123 2008 504 513
33. A. Jain, J. Reyes, R. Kashyap, S.F. Dodson, A.J. Demetris, and K. Ruppert et al. Long-term survival after liver transplantation in 4000 consecutive patients at a single center Ann Surg 232 2000 490 500
34. J.L. Dienstag, M.G. Ghany, and T.R. Morgan et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (HEP-10-2210) Hepatology 54 2011 396 405
35. Z.M. Younossi, M.E. Temple, and K.M. Shermock A pharmacoeconomic appraisal of therapies for hepatitis B and C Expert Opin Pharmacother 2 2001 205 211 [Review]
36. C. McAdam-Marx, L.J. McGarry, C.A. Hane, J. Biskupiak, B. Deniz, and D.I. Brixner All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective J Manag Care Pharm 17 2011 531 546
37. Top Picks (Most Requested Statistics): U.S. Bureau of Labor Statistics [Internet, cited 2013 Feb 12]. Available from: < http://data.bls.gov/cgi-bin/ surveymost?cu >.
38. Wholesale Acquisition Costs 2012 [Internet, cited 2013 Feb 12]. Available from: https://www.google.com/url?sa = t&rct = j&q = &esrc = s&source = web&cd = 2&ved = 0CDoQFjAB&url = http%3A%2F%2Fwww. fdhc.state.fl.us%2FMedicaid%2FPrescribed-Drug%2Fxls%2F2012Q2-Report-07-2612. xls&ei = sv8aUfFCgezzBOLhgZgL&usg = AFQjCNGYcJQeinNyZPuqGxXQOnhpwBEmzg&sig2 = 2pnyEVcYOMctfZ649guQVw&bvm = bv.42261806,d.eWU.
39. National Average Drug Acquisition Cost 2012. [Internet, cited 2013 Feb 12]. Available from: < http://www.medicaid.gov/Medicaid-CHIP-Program- Information/By-Topics/Benefits/Prescription-Drugs/Downloads/DRAFT-NADAC- 20121101.zip >.
40. C.A.K.Y. Chong, A. Gulamhussein, E.J. Heathcote, L. Lilly, M. Sherman, and G. Naglie et al. Health-state utilities and quality of life in hepatitis C patients Am J Gastroenterology 98 2003 630 638
41. K.E. Sherman, S.N. Sherman, T. Chenier, and J. Tsevat Health values of patients with chronic hepatitis C infection Arch Intern Med 164 2004 2377 2382
42. Z.M. Younossi, N. Boparai, M. McCormick, L.L. Price, and G. Guyatt Assessment of utilities and health-related quality of life in patients with chronic liver disease Am J Gastroenterol 96 2001 579 583
43. S. Liu, M. Schwarzinger, F. Carrat, and J.D. Goldhaber-Fiebert Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients PLoS One 6 2011 e26783
44. D.J. McLernon, J. Dillon, and P.T. Donnan Health-state utilities in liver disease: a systematic review Med Decis Making 28 2008 582 592
45. J. Ratcliffe, L. Longworth, T. Young, S. Bryan, A. Burroughs, and M. Buxton Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study Liver Transpl 8 2002 263 270
46. P. McEwan, R. Kim, and Y. Yuan Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model Appl Health Econ Health Policy 11 2013 53 63
47. F.A. Siddiqui, M.N. Ehrinpreis, J. Janisse, R. Dhar, E. May, and M.G. Mutchnick Demographics of a large cohort of urban chronic hepatitis C patients Hepatol Int 2 2008 376 381
48. CDC DVH - Hepatitis C FAQs for the Public [Internet, cited 2013 Mar 17]. Available from: < http://www.cdc.gov/hepatitis/c/cfaq.htm#cFAQ38 >.
49. CDC Features - hepatitis C testing for anyone born during 1945-1965: new CDC recommendations [Internet, cited 2013 Mar 17]. Available from: < http://www.cdc.gov/Features/HepatitisCTesting/ >.
50. V.A. Moyer on behalf of the U.S. Preventive services task force Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement Ann Intern Med 2013 10.7326/0003-4819-159-5-201309030- 00672